111In-Cetuximab-F(ab′)2 SPECT and 18F-FDG PET for Prediction and Response Monitoring of Combined-Modality Treatment of Human Head and Neck Carcinomas in a Mouse Model

@article{vanDijk2015111InCetuximabFab2SA,
  title={111In-Cetuximab-F(ab′)2 SPECT and 18F-FDG PET for Prediction and Response Monitoring of Combined-Modality Treatment of Human Head and Neck Carcinomas in a Mouse Model},
  author={Laura K van Dijk and Otto C Boerman and Gerben M. Franssen and Johannes H.A.M. Kaanders and Johan Bussink},
  journal={The Journal of Nuclear Medicine},
  year={2015},
  volume={56},
  pages={287 - 292}
}
Treatment of head and neck squamous cell carcinomas with radiotherapy and the epidermal growth factor receptor (EGFR) inhibitor cetuximab shows an improved response in a subgroup of patients. The aim of this study was to noninvasively monitor treatment response by visualizing systemically accessible EGFR with 111In-cetuximab-F(ab′)2 while simultaneously evaluating tumor metabolism with 18F-FDG PET during combined-modality treatment. Methods: Eighty mice with patient-derived head and neck… 

Figures from this paper

Affibody-Based PET Imaging to Guide EGFR-Targeted Cancer Therapy in Head and Neck Squamous Cell Cancer Models

TLDR
In vivo studies demonstrated that coinjecting 10 μg of nonlabeled molecules with 89Zr-deferoxamine-ZEGFR:03115 allows for clear tumor visualization 3 h after injection, and a strong correlation was observed between PET analysis, ex vivo estimates of tracer concentration, and receptor expression in tumor tissues.

Development and preclinical studies of 64Cu-NOTA-pertuzumab F(ab′)2 for imaging changes in tumor HER2 expression associated with response to trastuzumab by PET/CT

TLDR
PET/CT imaging with 64Cu-NOTA-pertuzumab F(ab′)2 detected changes in HER2 expression in response to trastuzumabs while delivering a lower total body radiation dose compared to 111In-labeled pertuzumAB.

Radiolabeled F(ab′)2-cetuximab for theranostic purposes in colorectal and skin tumor-bearing mice models

TLDR
111In-DOTAGA-F(ab′)2-cetuximab is a reliable and stable tool for specific in vivo tumor targeting and is suitable for therapy efficacy assessment.

Early Response Monitoring Following Radiation Therapy by Using [18F]FDG and [11C]Acetate PET in Prostate Cancer Xenograft Model with Metabolomics Corroboration

TLDR
TLG of [18F]FDG in vivo PET images can map early treatment response following irradiation and be a promising prognostic indicator in a longitudinal preclinical study.

Molecular Imaging in Head and Neck Squamous Cell Carcinoma Patients

TLDR
Developing of EGFR imaging with fluorescence and address preclinical imaging results in HNSCC models for other molecular targets, including integrin αvβ3 are addressed.

FDG-PET reproducibility in tumor-bearing mice: comparing a traditional SUV approach with a tumor-to-brain tissue ratio approach

TLDR
It is hypothesized that normalization of tumor FDG retention relative to a suitable reference tissue may improve accuracy as this method may be less susceptible to uncontrollable day-to-day changes in blood glucose levels, physical activity, or unnoticed imperfect tail vein injections.

PET and SPECT Imaging of the EGFR Family (RTK Class I) in Oncology

TLDR
Among these, engineered scaffold proteins and single domain antibodies show highly encouraging results in clinical studies marking a noticeable trend towards the use of smaller sized agents for HER imaging.

MicroSPECT/CT Imaging of Cell-Line and Patient-Derived EGFR-Positive Tumor Xenografts in Mice with Panitumumab Fab Modified with Hexahistidine Peptides to Enable Labeling with 99mTc (I) Tricarbonyl Complex.

We aimed to investigate the feasibility of conjugating synthetic hexahistidine peptides (His6) peptides to panitumumab Fab (PmFab) to enable labeling with [99mTc(H2O)3(CO)3]+ complex and study these

Molecular imaging of EGFR and CD44v6 for prediction and response monitoring of HSP90 inhibition in an in vivo squamous cell carcinoma model

TLDR
It is concluded that AT13387 downregulates HSP90 client proteins, and that molecular imaging of these proteins may be a suitable approach for assessing treatment response, and radioimmunotherapy targeting CD44v6 in combination with AT13388 may potentiate the radioim immunotherapy outcome due to radiosensitizing effects of the drug.

Targeted molecular imaging of head and neck squamous cell carcinoma: a window into precision medicine

TLDR
By visualizing tumor biomarkers at cellular and molecular levels in vivo, targeted molecular imaging can be used to identify specific genetic and metabolic aberrations, thereby accelerating personalized treatment development for HNSCC patients.

References

SHOWING 1-10 OF 34 REFERENCES

Early Response Monitoring with 18F-FDG PET and Cetuximab-F(ab′)2-SPECT After Radiotherapy of Human Head and Neck Squamous Cell Carcinomas in a Mouse Model

TLDR
EGFR accessibility can be visualized with 111In-cetuximab-F(ab′)2 SPECT before and after radiotherapy, implying that the tracer can be used to measure irradiation-induced changes of EGFR expression and can monitor the compensatory response of tumors to radiotherapy.

Imaging of Epidermal Growth Factor Receptor Expression in Head and Neck Cancer with SPECT/CT and 111In-Labeled Cetuximab-F(ab′)2

TLDR
The 111In-cetuximab-F(ab′)2 tracer to image EGFR targeting in vivo displays higher tumor-to-blood ratios early after injection than 111 in an HNSCC model, making it more suitable for EGFR visualization and potentially for selecting patients for treatment with EGFR inhibitors.

111In-cetuximab-F(ab')2 SPECT imaging for quantification of accessible epidermal growth factor receptors (EGFR) in HNSCC xenografts.

18F-FLT PET During Radiotherapy or Chemoradiotherapy in Head and Neck Squamous Cell Carcinoma Is an Early Predictor of Outcome

TLDR
In head and neck cancer, a change in 18F-FLT uptake early during radiotherapy or chemoradiotherapy is a strong indicator for long-term outcome and may aid in personalized patient management by steering treatment modifications during an early phase of therapy.

Exploratory prospective trial of hypoxia-specific PET imaging during radiochemotherapy in patients with locally advanced head-and-neck cancer.

  • D. ZipsK. Zöphel M. Baumann
  • Medicine, Physics
    Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  • 2012

Radiolabeled cetuximab: Dose optimization for epidermal growth factor receptor imaging in a head‐and‐neck squamous cell carcinoma model

TLDR
This study suggests that, at optimal cetuximab imaging dose, 111In‐cetUXimab can be used for visualization of EGFR expression in head‐and‐neck squamous cell carcinoma using SPECT.

Can "early" and "late"18F-FDG PET-CT be used as prognostic factors for the clinical outcome of patients with locally advanced head and neck cancer treated with radio-chemotherapy?

Early FDG PET at 10 or 20 Gy under chemoradiotherapy is prognostic for locoregional control and overall survival in patients with head and neck cancer

TLDR
The decrease of SUVmax from before (0 Gy) to week 1 or 2 (10 or 20  Gy) of CRT is a potential prognostic marker for patients with HNSCC and is suggested for the use of GTV PET, especially ΔSUVmax10/20, for an early estimation of therapy outcome.

Addition of 18F-FDG PET/CT to Clinical Assessment Predicts Overall Survival in HNSCC: A Retrospective Analysis with Follow-up for 12 Years

TLDR
18F-FDG PET/CT performed between 4 and 24 mo after treatment adds value to clinical assessment at the time of the study, especially when there is clinical suspicion or uncertainty, and can serve as a prognostic marker of OS in HNSCC.

PET Monitoring of Therapy Response in Head and Neck Squamous Cell Carcinoma

TLDR
Although 18F-FDG PET/CT will remain the major clinical tool for monitoring treatment in HNSCC, other PET probes may have a role in identifying patients who are likely to benefit from treatment strategies that include biologic agents such as epidermal growth factor receptor inhibitors or VEGF inhibitors.